Stelios Papadopoulos insider trades

Open-market stock purchases and sales by Stelios Papadopoulos, Director at Exelixis, Inc, from SEC Form 4 filings since May 19, 2010.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -17%.

Recent trades

DateStockTradeValue
May 27, 2026EXEL Exelixis, IncBought (not open market)—
Apr 7, 2026OVID Ovid Therapeutics IncBought (not open market)$45K
Feb 26, 2026OVID Ovid Therapeutics IncBought (not open market)—
Nov 12, 2025EXEL Exelixis, IncSold$4.4M

Companies traded

  • EXEL Exelixis, Inc: 16 buys, 15 sales, last May 27, 2026
  • OVID Ovid Therapeutics Inc: other filings, last Apr 7, 2026
  • RGLS Regulus Therapeutics Inc: 8 buys, last Jun 25, 2025
  • BIIB Biogen Inc: 1 buy, 5 sales, last Jun 15, 2022
  • EUCR Eucrates Biomedical Acquisition Corp: other filings, last Nov 24, 2020
  • BGMD BG Medicine, Inc: 6 buys, 6 sales, last Nov 18, 2015
  • "RGLS" Regulus Therapeutics Inc: other filings, last May 22, 2014
  • ANDS Anadys Pharmaceuticals Inc: other filings, last May 27, 2011

Get free alerts when Stelios Papadopoulos files a new trade →